Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2005

Jungbluth AA, Ely S, Diliberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005;106(1):167-74.

Witkiewicz AK, Hecht JL, Cviko A, McKeon FD, Ince TA, Crum CP. Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. Hum Pathol. 2005;36(2):154-61.

Best LG, Zhang Y, Lee ET, Yeh J-, Cowan L, Palmieri V, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005;112(9):1289-95.

Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol. 2005;32(9):616-21.

Varmus H, Pao W, Politi K, Podsypanina K, Du Y-. Oncogenes come of age. Cold Spring Harb Symp Quant Biol. 2005;70:1-9.

Lepley D, Paik J-, Hla T, Ferrer F. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res. 2005;65(9):3788-95.

Zhang J, Zhou P. Ectopic targeting of substrates to the ubiquitin pathway. Methods Enzymol. 2005;399:823-33.

Linger J, Tyler JK. The yeast histone chaperone chromatin assembly factor 1 protects against double-strand DNA-damaging agents. Genetics. 2005;171(4):1513-22.

Linares-Rodríguez JF, Martínez-Menéndez JL. [Antimicrobial resistance and bacterial virulence]. Enferm Infecc Microbiol Clin. 2005;23(2):86-93.

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23(24):5696-704.